Brain and Central Nervous System Cancers Clinical Studies

Some of the many Hematology/Oncology research opportunities available related to cancers of the brain and central nervous system (CNS) are listed below. Select a study to review a brief description and requirements. Parents or guardians of children who might be eligible are encouraged to inquire about enrollment. Contact information is provided at the end of each study.

Please note that Pilot and Phase I studies are the most experimental and should be considered only after other treatments or trials have been attempted without success.

Thank you for exploring these opportunities and helping us to find cures and prevent childhood disease.

Clinical Studies

Researchers

Brain Tumor Memory Study – Phase II

Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor

Read more

Central Nervous System Germ Cell Tumor Treatment with Chemotherapy and Radiation – Phase II

Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors

Read more

Central Nervous System Tumor Treatment with PD-0332991 – Phase I

A Study of CDK 4-6 Inhibitor PD-0332991 in Children with Recurrent, Progressive or Refractory Central Nervous System Tumors

Read more

Craniopharyngioma Treatment with PEGIntron – Phase II

Study of Peginterferon alfa-2b (PEGIntron) for Pediatric Patients with Unresectable or Recurrent Craniopharyngioma

Read more

DIPG Treatment with MK-1775 and Local Radiation – Phase I

MK-1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

Read more

Ependymoma Treatment with Maintenance Chemotherapy – Phase III

Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma

Read more

Ependymoma Vaccine Trial – Pilot

Treatment for Recurrent Ependymomas in Children Using HLA-A2 Restricted Tumor Antigen Peptides in Combination With Imiquimod

Read more

Glioma Treatment with Selumetinib (AZD6244) – Phase II

Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma

Read more

Glioma Treatment with Veliparib, Radiation and Temozolomide – Phase I/II

ABT-888, an Oral Poly (ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children with Newly Diagnosed Diffuse Pontine Gliomas

Read more

Gliomas Vaccine Study – Pilot

Treatment of Newly Diagnosed Brainstem Gliomas and Non-Brainstem High-Grade Gliomas, Recurrent Low-Grade and High-Grade Gliomas

Read more

High-Risk Medulloblastoma Treatment with Chemotherapy and Radiation – Phase III

Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients

Read more

Medulloblastoma and PNET Therapies with Temozolomide, Irinotecan, and Bevacizumab – Phase II

Temozolomide with Irinotecan versus Temozolomide, Irinotecan plus Bevacizumab for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial

Read more

Medulloblastoma Treatment with Carboplatin and Isotretinoin – Phase III

Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients

Read more

M0 Medulloblastoma Treatment in Young Children – Phase II

Study for the Treatment of Non-Metastatic Nodular Desmoplastic Medulloblastoma in Children Less Than 4 Years of Age

Read more

Pediatric Tumors and Specimen Study

A Children’s Oncology Group Protocol for Collecting and Banking Pediatric Specimens Including Rare Pediatric Tumors

Read more

Pilocytic Astrocytoma and Optic Pathway Glioma Treatment with Lenalidomide – Phase II

Trial of Lenalidomide in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas

Read more

Plexiform Neurofibromas Treatment with PEG-Intron - Phase II

Peginterferon alfa-2b in Treating Young Patients with Unresectable, Sympotomatic or Life-Threatening Plexiform Neurofibromas Associated with Neurofibromatosis Type 1

Read more

Solid Tumor and Lymphoma Treatment with PF-02341066 – Phases I and II

PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-MET, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma

Read more

Solid Tumor Treatment with MK-1775 – Phase I/II

MK-1775 in Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors

Read more

Linda M. McAllister-Lucas, MD, PhD

Read more

Cheryl A Hillery, MD

Read more

Debra E. Cohen, MD

Read more

James D Cooper, MD

Read more

Melvin Deutsch, MD

Read more

Erika Dawn Friehling, MD

Read more

James Anthony Graves, PhD, MD

Read more

Lynn M Malec, MD

Read more

Scott H Maurer, MD

Read more

Linda M. McAllister-Lucas, MD, PhD

Read more

Amma Twumwa Owusu-Ansah, MD

Read more

Edward V. Prochownik, MD, PhD

Read more

A. Kim Ritchey, MD

Read more

Jean M. Tersak, MD

Read more

Randy M Windreich, MD

Read more

Michael R. Wollman, MD

Read more